Investor Relations

Find the latest funding information here.

For media enquiries please contact info@allecra.com or call +41 79 592 2005

Allecra Therapeutics is a clinical stage biopharmaceutical company dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Its lead product candidate, which has been granted Fast Track Designation by the FDA, is completing Phase 2 clinical trials for the treatment of multi-drug-resistant Gram-negative bacterial infections in the hospital

17/04/2018 Allecra Therapeutics to present data at 28th European Congress of Clinical Microbiology and Infectious Diseases

Download PDF

03/04/2018 Allecra Therapeutics announces participation at the H.C. Wainwright annual global life sciences conference in Monte Carlo, Monaco on April 8-10,2018

Download PDF

26/03/2018 Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS
Study of its Lead Candidate, AAI101, in Combination with Cefepime to treat
complicated Urinary Tract Infections (cUTI)

Download PDF

14/02/2018 Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic in Resistant Infections

Download PDF

28/11/2017 Allecra Therapeutics Announces New Staged Financing Deal to Take the Company Through to End of Phase 3

Download PDF

09/06/2017 Allecra Announces Initiation of a Phase 2 Clinical Trial for its Novel Antibiotic to Treat Resistant Bacterial Infections

Download PDF

04/05/2017 Allecra Therapeutics Strengthens Leadership Team with Appointment of New Chairman and Chief Medical Officer

Download PDF

06/14/2016 Allecra Therapeutics Announces €22 Million Series B Financing

Download PDF

""